BioLife Solutions, Inc. (BLFS) Q3 2025 Earnings Call Transcript
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 06 2025
0mins
Should l Buy BLFS?
Source: SeekingAlpha
Cell Processing Revenue $25.4 million, a 33% year-over-year increase. The increase was driven by strong growth across the biopreservation media franchise and broader cell processing tools portfolio. Adjusting for a timing-related pull forward of $1.3 million, the year-over-year increase would have been 26%.
Total Revenue $28.1 million, representing a 31% year-over-year increase. The increase was primarily related to a 33% increase in the cell processing platform.
Adjusted EBITDA Margin 28%, a 500 basis points increase year-over-year. This improvement reflects the operating leverage inherent in the business model, driven by streamlined operations and a focused product portfolio.
GAAP Gross Margin 62%, compared to 63% in Q3 2024. The decrease was attributed to a $600,000 onetime inventory reserve and a less favorable product mix.
Adjusted Gross Margin 64%, compared to 67% in Q3 2024. The decrease was due to the $600,000 onetime inventory reserve and a less favorable product mix.
GAAP Operating Expenses $28.2 million, compared to $21.8 million in Q3 2024. The increase was due to higher cost of sales related to increased revenues and a $1.8 million increase in stock-based compensation expense.
Adjusted Operating Expenses $16.6 million, compared to $14.1 million in Q3 2024. The increase was attributed to higher revenues.
GAAP Operating Loss $89,000, compared to $418,000 in Q3 2024. The decrease was due to increased revenue.
Adjusted Operating Income $1.3 million, compared to $167,000 in Q3 2024. The increase was due to higher revenues.
GAAP Net Income $621,000 or $0.01 per share, compared to a GAAP net loss of $471,000 or $0.01 per share in Q3 2024. The increase was due to higher revenues.
Adjusted EBITDA $7.8 million or 28% of revenue, compared to $5 million or 23% of revenue in Q3 2024. The increase was driven by a $3.9 million increase in gross margin, which included a $600,000 onetime inventory reserve.
Cash and Marketable Securities $98.4 million as of September 30, 2025, compared to $100.2 million as of June 30, 2025. The decrease was due to capital expenditures, debt principal payments, and the purchase of a convertible promissory note.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BLFS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BLFS
Wall Street analysts forecast BLFS stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 18.670
Low
32.00
Averages
33.25
High
34.00
Current: 18.670
Low
32.00
Averages
33.25
High
34.00
About BLFS
BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioLife Solutions Reports Strong Q4 2025 Earnings Growth and Strategic Developments
- Significant Revenue Growth: BioLife Solutions reported total revenue of $96 million for 2025, reflecting a 29% year-over-year increase that exceeded expectations, driven by strong demand in the biopreservation market, particularly from commercial customers contributing nearly 50% of revenue.
- Improved Profitability: Q4 revenue reached $24.8 million, a 20% increase year-over-year, with adjusted EBITDA of $6.9 million, representing 28% of revenue, indicating ongoing enhancements in operational efficiency and profitability.
- Strategic Partnership Agreement: The company established a new distribution and product development agreement with QKine Limited for cytokines, which not only strengthens BioLife's product portfolio but also demonstrates its commitment to growth through strategic collaborations and acquisitions.
- Optimistic 2026 Outlook: Management anticipates total revenue for 2026 to be between $112 million and $115 million, representing a growth rate of 17% to 20%, and expects to achieve GAAP net income for the first time, highlighting strong prospects driven by commercial customer demand and new product initiatives.
See More
BioLife (BLFS) Q4 2025 Earnings Call Transcript
See More
BioLife Solutions Set to Announce Q4 Earnings
- Earnings Announcement Date: BioLife Solutions is scheduled to release its Q4 earnings on February 26 after market close, with investors keenly awaiting the results to assess the company's future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at $0.01, reflecting a substantial year-over-year increase of 125%, indicating a significant improvement in the company's profitability that may attract more investor interest.
- Revenue Projections: The consensus revenue estimate is $24.01 million, representing a 5.8% year-over-year growth, which highlights the company's stable growth in the bioproducts market and enhances its competitive position.
- Analyst Ratings: Seeking Alpha's Quant Rating on BioLife Solutions will provide investors with additional insights for decision-making, helping them better understand the company's financial health and future direction.
See More
BioLife Solutions Reports Q4 Revenue of $24.8M, Up 20% Year-Over-Year
- Significant Revenue Growth: BioLife Solutions reported preliminary Q4 unaudited revenue from continuing operations of $24.8 million, reflecting a 20% year-over-year increase, which underscores the company's strong performance in the cell and gene therapy market and solidifies its market position.
- Full-Year Performance Exceeds Expectations: For FY2025, the company achieved $96.2 million in continuing operations revenue, surpassing the high end of previously raised guidance by 29%, indicating robust growth driven by its biopreservation product line and boosting investor confidence.
- Strategic Focus Transformation: Following the divestiture of the evo product line in 2025, BioLife is now positioned as a pure-play cell processing company focused on high-value, recurring revenue franchises, which is expected to drive future profitability and long-term value creation.
- Optimistic Future Outlook: The company anticipates revenue growth across its product portfolio in 2026, along with further expansion of adjusted EBITDA margins, indicating sustained competitiveness and profitability in the market.
See More
Pinnacle Financial Partners Trading 32.3% Below Fair Value Amid Growth Prospects
- Market Strength: As of the end of 2025, the U.S. stock market is notably strong, with the S&P 500 reaching all-time highs, reflecting investor confidence amid rising precious metal prices and stable Treasury yields.
- Pinnacle Financial Overview: Pinnacle Financial Partners has a market cap of $7.79 billion and generates $1.89 billion in annual revenue, with earnings and revenue expected to grow significantly over the next three years, despite a low forecasted return on equity of 11.3%.
- M&A Impact: The recent regulatory approval for Pinnacle's merger with Synovus Financial Corp is expected to positively influence future performance, with integration efforts projected to be completed by 2027, enhancing market competitiveness.
- Other Undervalued Stocks: In the U.S. market, companies like Zymeworks, UMB Financial, and Sportradar show significant undervaluation potential, with estimated discounts ranging from 48% to 49%, attracting investor interest.
See More
Workday and Dycom Industries Highlighted as Undervalued with Significant Growth Potential
- Workday Valuation Insight: Workday's current price of $216.85 is significantly below its fair value of $347.1, indicating a 37.5% undervaluation; despite a drop in profit margins from 19.9% to 7%, earnings are projected to grow at 32.2% annually, well above the U.S. market's 16.2% growth rate.
- Dycom Future Outlook: Dycom Industries is trading at $348.4, below its estimated fair value of $452.77, reflecting a 23.1% undervaluation; despite high debt levels, earnings grew by 32.7% over the past year, with an expected annual growth rate of 18.1%, surpassing the market average.
- FIS Financial Health: Fidelity National Information Services is priced at $67.17, significantly below its fair value of $114.18, highlighting a 41.2% undervaluation; despite a decline in profit margins to 1.7%, earnings are forecasted to grow at 47.6% annually, far exceeding the market average.
- Market Opportunities: In a robust market where the Dow Jones and S&P 500 have reached new highs, investors are actively seeking undervalued stocks, with Workday, Dycom, and FIS presenting significant potential for substantial returns.
See More
BioLife Solutions Reports Strong Q4 2025 Earnings Growth and Strategic Developments
- Significant Revenue Growth: BioLife Solutions reported total revenue of $96 million for 2025, reflecting a 29% year-over-year increase that exceeded expectations, driven by strong demand in the biopreservation market, particularly from commercial customers contributing nearly 50% of revenue.
- Improved Profitability: Q4 revenue reached $24.8 million, a 20% increase year-over-year, with adjusted EBITDA of $6.9 million, representing 28% of revenue, indicating ongoing enhancements in operational efficiency and profitability.
- Strategic Partnership Agreement: The company established a new distribution and product development agreement with QKine Limited for cytokines, which not only strengthens BioLife's product portfolio but also demonstrates its commitment to growth through strategic collaborations and acquisitions.
- Optimistic 2026 Outlook: Management anticipates total revenue for 2026 to be between $112 million and $115 million, representing a growth rate of 17% to 20%, and expects to achieve GAAP net income for the first time, highlighting strong prospects driven by commercial customer demand and new product initiatives.
See More
BioLife (BLFS) Q4 2025 Earnings Call Transcript
See More
BioLife Solutions Set to Announce Q4 Earnings
- Earnings Announcement Date: BioLife Solutions is scheduled to release its Q4 earnings on February 26 after market close, with investors keenly awaiting the results to assess the company's future growth potential.
- Earnings Expectations: The consensus EPS estimate stands at $0.01, reflecting a substantial year-over-year increase of 125%, indicating a significant improvement in the company's profitability that may attract more investor interest.
- Revenue Projections: The consensus revenue estimate is $24.01 million, representing a 5.8% year-over-year growth, which highlights the company's stable growth in the bioproducts market and enhances its competitive position.
- Analyst Ratings: Seeking Alpha's Quant Rating on BioLife Solutions will provide investors with additional insights for decision-making, helping them better understand the company's financial health and future direction.
See More
BioLife Solutions Reports Q4 Revenue of $24.8M, Up 20% Year-Over-Year
- Significant Revenue Growth: BioLife Solutions reported preliminary Q4 unaudited revenue from continuing operations of $24.8 million, reflecting a 20% year-over-year increase, which underscores the company's strong performance in the cell and gene therapy market and solidifies its market position.
- Full-Year Performance Exceeds Expectations: For FY2025, the company achieved $96.2 million in continuing operations revenue, surpassing the high end of previously raised guidance by 29%, indicating robust growth driven by its biopreservation product line and boosting investor confidence.
- Strategic Focus Transformation: Following the divestiture of the evo product line in 2025, BioLife is now positioned as a pure-play cell processing company focused on high-value, recurring revenue franchises, which is expected to drive future profitability and long-term value creation.
- Optimistic Future Outlook: The company anticipates revenue growth across its product portfolio in 2026, along with further expansion of adjusted EBITDA margins, indicating sustained competitiveness and profitability in the market.
See More
Pinnacle Financial Partners Trading 32.3% Below Fair Value Amid Growth Prospects
- Market Strength: As of the end of 2025, the U.S. stock market is notably strong, with the S&P 500 reaching all-time highs, reflecting investor confidence amid rising precious metal prices and stable Treasury yields.
- Pinnacle Financial Overview: Pinnacle Financial Partners has a market cap of $7.79 billion and generates $1.89 billion in annual revenue, with earnings and revenue expected to grow significantly over the next three years, despite a low forecasted return on equity of 11.3%.
- M&A Impact: The recent regulatory approval for Pinnacle's merger with Synovus Financial Corp is expected to positively influence future performance, with integration efforts projected to be completed by 2027, enhancing market competitiveness.
- Other Undervalued Stocks: In the U.S. market, companies like Zymeworks, UMB Financial, and Sportradar show significant undervaluation potential, with estimated discounts ranging from 48% to 49%, attracting investor interest.
See More
Workday and Dycom Industries Highlighted as Undervalued with Significant Growth Potential
- Workday Valuation Insight: Workday's current price of $216.85 is significantly below its fair value of $347.1, indicating a 37.5% undervaluation; despite a drop in profit margins from 19.9% to 7%, earnings are projected to grow at 32.2% annually, well above the U.S. market's 16.2% growth rate.
- Dycom Future Outlook: Dycom Industries is trading at $348.4, below its estimated fair value of $452.77, reflecting a 23.1% undervaluation; despite high debt levels, earnings grew by 32.7% over the past year, with an expected annual growth rate of 18.1%, surpassing the market average.
- FIS Financial Health: Fidelity National Information Services is priced at $67.17, significantly below its fair value of $114.18, highlighting a 41.2% undervaluation; despite a decline in profit margins to 1.7%, earnings are forecasted to grow at 47.6% annually, far exceeding the market average.
- Market Opportunities: In a robust market where the Dow Jones and S&P 500 have reached new highs, investors are actively seeking undervalued stocks, with Workday, Dycom, and FIS presenting significant potential for substantial returns.
See More
